MMJ Federal Lawsuit Challenges DEA Rescheduling Timeline

Lawsuit Targets Procedural Shortcuts in Final Rule

MMJ Federal's complaint alleges the DEA unlawfully truncated the rescheduling process by issuing a final rule without holding a second round of public hearings after receiving over 43,000 comments on the proposed rule. The suit was filed in the U.S. District Court for the District of Columbia. It names DEA Administrator Anne Milgram and Attorney General Merrick Garland as defendants.

The complaint centers on the DEA's May 2026 final rule, which moved cannabis to Schedule III effective July 1, 2026. MMJ Federal argues the agency was required under 21 U.S.C. § 811(a) to hold a second public hearing after the comment period closed in March 2026, particularly given the volume and substance of opposition comments from law enforcement groups, addiction medicine organizations, and several state attorneys general.

According to the 47-page complaint, the DEA cited "urgent public health considerations" and "executive directive" as justification for bypassing the second hearing. The Trump administration had publicly pressured the DEA to finalize rescheduling before the 2026 midterm elections. MMJ Federal's legal team includes former DOJ attorney Sarah Pullen, who served as deputy assistant attorney general in the Office of Legal Counsel from 2017 to 2021.

Administrative Record Shows Internal DEA Objections

The lawsuit cites internal DEA emails obtained through FOIA showing career staff attorneys warned leadership in April 2026 that skipping the second hearing created "significant litigation risk" under the APA's arbitrary-and-capricious standard. One email from DEA Chief Counsel Timothy Landrum to Administrator Milgram, dated April 18, 2026, states: "We have no precedent for a Schedule I-to-III move without dual hearings. This won't survive Chevron step two."

The administrative record filed with the complaint includes a March 2026 memo from the DEA's Office of Diversion Control recommending a 90-day extension of the comment period and a second hearing in June 2026. Milgram overruled that recommendation on March 28, 2026, according to a one-page decision memo that states only: "Proceeding to final rule. No second hearing warranted."

MMJ Federal isn't a cannabis-industry trade group. It's a 501(c)(4) advocacy organization founded in 2003 that has historically opposed state medical marijuana programs and federal rescheduling. The group's board includes former DEA agents, addiction psychiatrists, and Kevin Sabet, co-founder of Smart Approaches to Marijuana. The lawsuit doesn't seek to block rescheduling outright but asks the court to vacate the final rule and remand to the DEA for a compliant process.

Implications for MSOs and 280E Relief

If the court grants MMJ Federal's motion for summary judgment, the DEA would be required to restart the rescheduling process from the proposed-rule stage, pushing any final Schedule III designation into 2028 at the earliest. That timeline would delay federal tax relief under IRC § 280E for multi-state operators, which have been booking the Schedule III tax benefit since Q3 2026 earnings.

Curaleaf, Trulieve, Green Thumb Industries, and Verano reported a combined $340 million in projected 280E savings for fiscal 2026 in their August 2026 10-Q filings. Those projections assumed Schedule III status remained in effect for the full fiscal year. A vacatur of the final rule would require those MSOs to restate earnings and re-book the 280E expense, likely triggering going-concern warnings for the two operators carrying over $500 million in term debt.

Judge Tanya Chutkan drew the case. She's ruled against the DEA in three prior APA challenges since 2022. Oral argument on the motion for preliminary injunction is set for September 12, 2026. The DEA has until August 30 to file its opposition brief. For full background on the rescheduling process and timeline, see the CannIntel topic hub on DEA rescheduling.

The Trump administration hasn't yet commented publicly on the lawsuit. A DOJ spokesperson said the department "will vigorously defend the final rule" but declined to address the procedural arguments on the record. The next signal: whether DOJ seeks to transfer venue out of the D.C. Circuit, where the agency has lost four of its last five cannabis-related APA cases.